Skip to main content

Table 6 PRO mean changes from baseline to week 52, reported by patients experiencing ≥ 1 acute exacerbation and those experiencing no acute exacerbations over the study period (analysis 2)

From: Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSIS® trials

 Mean change from baseline to week 52
No acute exacerbations≥ 1 acute exacerbation
SGRQ total score3.18 (n = 808)16.53** (n = 28)
SGRQ symptom score1.93 (n = 829)11.09 (n = 29)
SGRQ activity score4.53 (n = 821)12.44 (n = 28)
SGRQ impacts score3.13 (n = 818)21.27*** (n = 28)
UCSD-SOBQ6.20 (n = 735)22.00* (n = 23)
CASA-Q cough symptom scorea−0.63 (n = 835)0.86 (n = 29)
CASA-Q cough impact scorea−2.37 (n = 835)− 8.94 (n = 29)
EQ-5D VASa− 3.65 (n = 821)−7.31 (n = 29)
  1. CASA-Q cough and sputum assessment questionnaire (symptom and impact score), EQ-5D VAS EuroQoL 5-dimensional quality of life questionnaire visual analog scale, FVC forced vital capacity, PRO patient-reported outcome, SGRQ St George’s respiratory questionnaire (total, symptoms, activity and impacts score), UCSD-SOBQ University of California San Diego shortness of breath questionnaire
  2. *P < 0.05;**P < 0.01; and ***P < 0.001 vs ‘no acute exacerbations’ group
  3. aDecrease in score indicates worsening health